2024
Epidemiology and risk factors for hyperkalaemia in heart failure
Grobbee D, Filippatos G, Desai N, Coats A, Pinto F, Rosano G, Cleland J, Kammerer J, de Arellano A. Epidemiology and risk factors for hyperkalaemia in heart failure. ESC Heart Failure 2024, 11: 1821-1840. PMID: 38439165, PMCID: PMC11287317, DOI: 10.1002/ehf2.14661.Peer-Reviewed Original ResearchHeart failureObservational studyRisk factorsRenin-angiotensin-aldosterone system inhibitorsSevere renal impairmentElevated serum potassiumImpaired renal functionRisk of hyperkalaemiaIncreased risk of mortalityAdverse cardiovascular eventsClinical epidemiological dataFollow-up lengthChronic kidney diseaseRisk of mortalityIdentified risk factorsMild hyperkalaemiaPotassium bindersRenal impairmentConcomitant medicationsHF therapyDiagnosed HFRenal functionSerum potassiumClinical careClinical outcomes
2023
Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use
Clark K, Victoria-Castro A, Ghazi L, Yamamoto Y, Coronel-Moreno C, Kadhim B, Riello R, O'Connor K, Ahmad T, Wilson F, Desai N. Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use. JACC Heart Failure 2023, 12: 322-332. PMID: 37943221, DOI: 10.1016/j.jchf.2023.08.025.Peer-Reviewed Original ResearchBest practice alertMineralocorticoid receptor antagonistsNovel potassium bindersPotassium bindersEligible patientsUsual careEjection fractionSerum potassiumHistory of hyperkalemiaIncidence of hyperkalemiaStrong guideline recommendationsHeart failure hospitalizationReduced ejection fractionLaboratory test valuesPopulation health outcomesHyperkalemia treatmentMRA prescriptionAntagonist useFailure hospitalizationPatient characteristicsSecondary outcomesHeart failurePrimary outcomeGuideline recommendationsOutpatient visits
2020
Baseline and on-treatment serum potassium and mortality in high risk patients: the Systolic Blood Pressure Intervention Trial (SPRINT)
Byrne C, Pareek M, Biering-Soerensen T, Vaduganathan M, Krogager M, Kragholm K, McCullough M, Desai N, Olsen M, Bhatt D. Baseline and on-treatment serum potassium and mortality in high risk patients: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal 2020, 41: ehaa946.2732. DOI: 10.1093/ehjci/ehaa946.2732.Peer-Reviewed Original ResearchSystolic Blood Pressure Intervention TrialIntensive blood pressure loweringBlood pressure loweringSerum potassium levelsIntensive blood pressureSerum potassiumPressure loweringPotassium levelsCV causesMultivariable adjustmentBlood pressureSystolic blood pressure 130End-stage renal diseaseBaseline serum potassiumLong-time mortalityShort-time mortalityStandard antihypertensive treatmentHigh cardiovascular riskHigh-risk patientsGlomerular filtration rateYears of ageSerum potassium measurementsAntihypertensive treatmentCardiovascular riskRenal function